Overview

The prevalence of Metabolic Dysfunction-Associated Steatohepatitis (MASH, formerly known as NASH) is increasing. Recognizing patients at risk for MASH is important for early screening and diagnosis. 

SPONSORED BY

Boehringer Ingelheim Pharmaceuticals, Inc.